Short answer: retatrutide is not ARTG-registered in Australia as of 2026, so it cannot be lawfully bought from an Australian pharmacy as a finished product. It can be prescribed lawfully on a per-case basis via the TGA Special Access Scheme Category B (SAS-B) by an AHPRA-registered Australian doctor and dispensed by a TGA-licensed compounding pharmacy — but that is the only lawful Australian pathway. Buying retatrutide from offshore "research peptide" sites is illegal, regardless of how the seller labels the vial.
Why retatrutide is not on the ARTG: it is still in phase 3 clinical trials. Eli Lilly's TRIUMPH program (TRIUMPH-1, -2, -3, -4) is generating the long-term efficacy and safety data needed to support a US FDA submission, expected across 2025–2026. The TGA generally aligns with FDA timing for novel molecules, so ARTG registration is unlikely before 2027–2028. Until then, retatrutide does not have a TGA marketing approval — which is the regulatory precondition for routine pharmacy supply.
What the SAS-B pathway means here: SAS-B is the TGA mechanism that lets an AHPRA-registered Australian doctor prescribe an unapproved therapeutic good for an individual patient on a case-by-case basis. The prescriber lodges a notification with the TGA, keeps a clinical record, and carries professional responsibility for the decision. In principle, an Australian doctor can lodge an SAS-B notification for retatrutide. In practice, most prescribers will not — because Mounjaro (tirzepatide) and Wegovy (semaglutide) are ARTG-registered, have established long-term data, and cover the clinical indication that drives most retatrutide enquiries (weight management). The professional bar for "I am prescribing a phase-3 molecule under SAS-B" is high.
Free guide: Legal Peptides in Australia (2026)
What's legal under TGA SAS-B, which peptides Australian doctors actually prescribe, real costs, and the questions to ask at your consult.
No spam. Unsubscribe any time. See our privacy policy.
What about "Australian retatrutide" websites? Sites including retatrutide.com.au, australianpeptidestore, purepeptix and similar are not AHPRA-licensed prescribers and not TGA-licensed compounding pharmacies. They sell retatrutide as a "research peptide" to dodge the regulatory framework — but Australian Schedule 4 law applies to the substance, not the marketing label. Buying, possessing, or importing retatrutide outside the lawful AHPRA → SAS-B → TGA-licensed-pharmacy pathway is an offence under state Poisons Acts and the Customs Act. Australian Border Force routinely seizes parcels from offshore peptide sellers; the buyer carries the criminal exposure, not the offshore seller.
What about clinical risk? "Research peptide" product has no validated identity (you cannot confirm the vial contains retatrutide, the correct dose, or anything at all), no sterility guarantee (abscesses and bacterial infections from contaminated injection have been documented), no endotoxin testing, and no Australian medical record of treatment. If something goes wrong, you have no prescriber to manage it.
What should an Australian patient asking about retatrutide actually do in 2026? Book a telehealth consult with an AHPRA-registered Australian doctor and have the full conversation. For most weight-management cases, the clinically appropriate option is Mounjaro (tirzepatide) on a private script, or Wegovy (semaglutide for weight loss). Both are ARTG-registered, both have published long-term outcomes, both ship from Australian pharmacies. If you have specific clinical reasons that a triple-agonist would change the picture for you, raise it at the consult — the doctor can explain whether SAS-B retatrutide is realistic for your case or whether you are better served waiting for ARTG approval.
The short version: retatrutide is not illegal in Australia in 2026, but it is also not freely available. There is one lawful path (AHPRA doctor → SAS-B → TGA-licensed compounding pharmacy) and many illegal ones (every offshore "research peptide" site). The legal path is also the only one with sterile, identity-verified, prescriber-supervised medicine.